Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Roth Capital analyst Boobalan Pachaiyappan maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price tar...
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of...
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, P...
–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality cont...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ: CAPR) with a Buy and maintains $2...
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its r...
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025...
